Better Therapeutics Inc (BTTX) Noticias

Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic...

Form 8-K - Current report

Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes...

Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification...

Form 8-K - Current report

Form RW - Registration Withdrawal Request

Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Signifies the FDA’s recognition of the Company’s novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment

Agreement is an important step towards securing broad coverage Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form D - Notice of Exempt Offering of Securities

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Over a lifetime horizon AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report